Takeda, M., & Nakagawa, K. (2019). First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? Int J Mol Sci.
Citação norma ChicagoTakeda, Masayuki, and Kazuhiko Nakagawa. "First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?" Int J Mol Sci 2019.
MLA CitationTakeda, Masayuki, and Kazuhiko Nakagawa. "First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?" Int J Mol Sci 2019.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.